Correlation Between Prostatype Genomics and CellaVision

Can any of the company-specific risk be diversified away by investing in both Prostatype Genomics and CellaVision at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Prostatype Genomics and CellaVision into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Prostatype Genomics AB and CellaVision AB, you can compare the effects of market volatilities on Prostatype Genomics and CellaVision and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Prostatype Genomics with a short position of CellaVision. Check out your portfolio center. Please also check ongoing floating volatility patterns of Prostatype Genomics and CellaVision.

Diversification Opportunities for Prostatype Genomics and CellaVision

0.47

Correlation Coefficient

Prostatype Genomics  CellaVision

Very weak diversification

The 3 months correlation between Prostatype and CellaVision is 0.47. Overlapping area represents the amount of risk that can be diversified away by holding Prostatype Genomics AB and CellaVision AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CellaVision AB and Prostatype Genomics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Prostatype Genomics AB are associated (or correlated) with CellaVision. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CellaVision AB has no effect on the direction of Prostatype Genomics i.e., Prostatype Genomics and CellaVision go up and down completely randomly.

Pair Corralation between Prostatype Genomics and CellaVision

Assuming the 90 days trading horizon Prostatype Genomics AB is expected to generate 6.48 times more return on investment than CellaVision. However, Prostatype Genomics is 6.48 times more volatile than CellaVision AB. It trades about 0.07 of its potential returns per unit of risk. CellaVision AB is currently generating about -0.1 per unit of risk. If you would invest  93.00  in Prostatype Genomics AB on May 8, 2025 and sell it today you would earn a total of  6.00  from holding Prostatype Genomics AB or generate 6.45% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Prostatype Genomics AB  vs.  CellaVision AB

Prostatype Genomics

Risk-Adjusted Performance

Mild

Compared to the overall equity markets, risk-adjusted returns on investments in Prostatype Genomics AB are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain basic indicators, Prostatype Genomics sustained solid returns over the last few months and may actually be approaching a breakup point.

CellaVision AB

Risk-Adjusted Performance

Weakest

Over the last 90 days CellaVision AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest uncertain performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

Pair Trading with Prostatype Genomics and CellaVision

The main advantage of trading using opposite Prostatype Genomics and CellaVision positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Prostatype Genomics position performs unexpectedly, CellaVision can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CellaVision will offset losses from the drop in CellaVision's long position.

The idea behind Prostatype Genomics AB and CellaVision AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.